

Baird 2018 Global Healthcare Conference

Jon Stonehouse
Chief Executive Officer

Dr. William Sheridan
Chief Medical Officer

September 6, 2018




Forward Looking Statements

BioCryst's presentation may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors that may cause BioCryst's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect BioCryst's current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that the remaining cohorts of the ongoing ZENITH-1 trial may not be completed as expected; that the current results of the ZENITH-1 trial may not be predictive of future results, including the results of the remaining cohorts of ZENITH-1 and the APeX-2, APeX-S, and APeX-J trials; that developing BCX7353 for acute or prophylactic treatment may take longer or be more expensive than planned or may ultimately be unsuccessful; that producing a commercial formulation of BCX7353 may take longer than expected or may not occur as planned; that the Food and Drug Administration or other regulatory agencies may require additional studies beyond the studies currently planned, may not support trial designs, or may not provide regulatory clearances, which could result in delay of planned clinical trials; that we may never obtain market approval for BCX7353 or that commercialization of BCX7353 may ultimately be unsuccessful. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst's projections and forward-looking statements.

Delivering extraordinary Empowering ordinary

BioCryst develops novel oral medicines designed to treat rare disease to help patients experience a normal quality of life.

Multiple Anticipated Milestones



BioCryst's Robust Pipeline

	Lead Optimization	Pre-clinical	Phase 1	Phase 2	Phase 3	Filed	Approved
STRATEGY: Develop oral therapies for life-threatening, rare diseases							
BCX7353 – Oral Capsule (Prophylactic HAE)							
BCX7353 – Oral Formulation (Acute HAE)							
BCX9250 & BCX9499 (FOP)							
Other rare diseases							
SUPPORTING ASSETS: Externally funded, potential for capital infusions							
RAPIVAB® (peramivir injection)*							
Galidesivir (Broad spectrum antiviral) I.V.							

*Licensed to Seqirus, Shionogi and Green Cross

Strong Financial Position

(In millions)

Cash & investments at December 31, 2017	\$159
Cash & investments at June 30, 2018	\$122
Pro-forma cash & investments at June 30, 2018 ^A	\$186
Senior Credit Facility ^B	\$30
FY 2018 GUIDANCE (stand-alone, as revised on July 11, 2018)	
Operating cash utilization	\$85 – 105
Operating expenses ^C	\$90 – 110

^A – Includes proceeds from the July credit facility enhancement and the August public offering.

^B – Credit Facility was enhanced in July 2018.


^C - Excludes equity-based compensation.

CDC Awards BioCryst \$35 Million RAPIVAB® Contract for Strategic National Stockpile

- \$34.7 million CDC contract for procurement of up to 50,000 doses over a five-year period
- Will supply the Strategic National Stockpile
- Provides additional non-dilutive capital to advance pipeline



BCX7353 - A **New Approach** to Hereditary Angioedema Treatment



Unpredictable,
debilitating, potentially
life-threatening swelling
attacks

1 in 50,000 people
affected worldwide

\$2 Billion projected
global market opportunity

BCX7353 is an oral **once
daily** selective inhibitor of
plasma kallikrein currently
in Phase 3

Regulatory Agency Status for BCX7353



- Orphan Drug Designation 2017
- EOP2 2017
- Fast Track Designation



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

- Orphan Drug Designation 2018
- National Scientific Advice 2018
- Scientific Advice Process (EOP2 Equivalent) 2017



- UK Promising Innovative Medicine (PIM) 2018



- Formal Consultation Process (EOP2 equivalent) 2018
- Sakigake Designation 2015

BCX7353 phase 2 APeX-1 trial published, phase 3 trial well underway

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema

E. Aygören-Pürsün, A. Bygum, V. Grivcheva-Panovska, M. Magerl, J. Graff, U.C. Steiner, O. Fain, A. Huissoon, T. Kinaciyan, H. Farkas, R. Leonart, H.J. Longhurst, W. Rae, M. Triggiani, W. Aberer, M. Cancian, A. Zanichelli, W.B. Smith, M.L. Baeza, A. Du-Thanh, M. Gompels, T. Gonzalez-Quevedo, J. Greve, M. Guilarte, C. Katelaris, S. Dobo, M. Cornpropst, D. Clemons, L. Fang, P. Collis, W. Sheridan, M. Maurer, and M. Cicardi

Aygoren-Pursun, E. et al 2018 *N Engl J Med* **379**(4): 352-362



Blinded Treatment
24 weeks

N \cong 32 BCX7353 150 mg QD*


N \cong 32 BCX7353 110 mg QD*

N \cong 32 Placebo QD

Final analysis @ week 24

APeX-1: Overall Angioedema Attack Rate per Week, PP Population, Weeks 2-4 and 1-4

Attack Rate: LS Mean Attacks/Week



	62.5mg	125mg	250mg	350mg
WEEKS 2 - 4				
% Difference, Active-PBO	-9%	-74%	-47%	-58%
p-Value	0.657	<0.001	0.005	<0.001
WEEKS 1 - 4				
% Difference, Active-PBO	-4%	-70%	-54%	-50%
p-Value	0.818	<0.001	<0.001	<0.001

APeX-1: Treatment-Emergent Adverse Event Summary

Category	BCX7353				Placebo N = 22
	62.5 mg N = 7	125 mg N = 14	250 mg N = 14	350 mg N = 18	
Subjects with any TEAE ¹ , n (%)	4 (57)	7 (50)	11 (79)	14 (78)	15 (68)
Subjects with any Serious AE, n (%)	0	0	1 (7) ²	0	0
Subjects with Drug-Related Grade 3 AE, n (%)	0	0	0	1 (6)	0
Subjects with AE Leading to D/C from Study Drug, n (%)	0	0	0	3 (17)	0
Non-drug-related, n (%)	0	0	0	1 (6) ³	0
Drug-related, n (%)	0	0	0	2 (11) ^{4,5}	0

¹ TEAE- treatment-emergent adverse event.


² GI infection- investigator assessed as unrelated to study drug. Abdominal symptoms similar to several previous non-HAE-attack episodes occurring over past 3 years resulting in severe vomiting and diarrhea. Pt presented to ER and hospitalized for IV fluids and antiemetics as a precaution. No HAE acute attack meds given. Recovered and discharged the following day. Missed 1 day of dosing due to event.

³ Pre-existing liver disorder (improved from baseline, but persisting). Previously reported in 1st interim analysis.

⁴ n=1 Gastroenteritis with liver disorder (both assessed as related) (elevated ALT 1.9x ULN, GGT 5.4x ULN and ALP 1.6x ULN, with normal AST and bilirubin). Previously reported in 1st interim analysis.


⁵ n=1 Vomiting/abdominal cramps. Previously reported in 2nd interim analysis.

APeX-2: Phase 3 Trial Design



*Doses in Phase 2 APeX-1 were shown as the dihydrochloride salt:
150 mg = 175 mg dihydrochloride salt; 110 mg = 125 mg dihydrochloride salt

APeX-2: Phase 3 Trial Design – Safety Extension



*Doses in Phase 2 APeX-1 were shown as the dihydrochloride salt:
150 mg = 175 mg dihydrochloride salt; 110 mg = 125 mg dihydrochloride salt

APeX-S: Long-term Safety Study Design



48 Weeks Treatment

N \cong 80 BCX7353 150 mg QD

N \cong 80 BCX7353 110 mg QD

Analyses as needed for
regulatory submissions



◆ Endpoints:

- Long term safety of BCX7353
- Durability of response
- Quality of Life

◆ APeX-1 subjects eligible

◆ Safety database:

- Up to 100 subjects at each dose level
- Combination of APeX-2 extension and APeX-S


*Doses in Phase 2 APeX-1 were shown as the dihydrochloride salt:
150 mg = 175 mg dihydrochloride salt; 110 mg = 125 mg dihydrochloride salt

Dr. William Sheridan

Chief Medical Officer



Angioedema Attacks in HAE Need Early Treatment to Prevent Severe Disability



¹ Modified from Bork, K. 2006. *Am J Gastroenterol* **101**(3): 619-627

Original Article

US Hereditary Angioedema Association Medical Advisory Board 2013 Recommendations for the Management of Hereditary Angioedema Due to C1 Inhibitor Deficiency


Bruce L. Zuraw, MD^{a,b}, Aleena Banerji, MD^c, Jonathan A. Bernstein, MD^d, Paula J. Busse, MD^e, Sandra C. Christiansen, MD^{a,f}, Mark Davis-Lorton, MD^g, Michael M. Frank, MD^h, Henry H. Li, MDⁱ, William R. Lumry, MD^j, and Marc Riedl, MD^k La Jolla, San Diego, and Los Angeles, Calif; Boston, Mass; Cincinnati, Ohio; New York and Mineola, NY; Durham, NC; Chevy Chase, Md; and Dallas, Tex

“On-demand treatment of attacks is most effective when administered early in the attack. Patients should be counseled to treat as soon as the attack is clearly recognized.”²

² Zuraw, B. L. 2013 *J Allergy Clin Immunol Pract* **1**(5): 458-467

ZENITH-1 Phase 2 Placebo-controlled Trial of At-home Self-administered Oral Treatment

Trial methods are aligned with the current guidelines for on-demand treatment^{1,2}



Subjects in Part 1	N
Subjects randomized	36
Subjects treated	33
Completed 3 on-study attacks	30

Attacks in Part 1	BCX7353	Placebo
Attacks treated, N	64	31
Time from onset of symptoms to study drug administration, min median (range)	35 (10-90)	35 (10-90)
Baseline mean VAS score	14.0	15.0




ZENITH-1 is unique – designed to conform with current treatment paradigm of on-demand Rx

Drug Study	Cinryze <i>CHANGE</i>	Berinert <i>IMPACT-1</i>	Kalbitor <i>EDEMA-3</i>	Firazyr <i>FAST-3</i>	Ruconest <i>C-1310 Trial</i>	BCX7353 <i>ZENITH-1</i>
Years subjects enrolled	2005-2007	2005-2007	2005-2007	2009-2010	2011-2012	2017-2018
Route	IV infusion	IV infusion	SC injection	SC injection	IV infusion	PO (liquid)
Duration of symptoms prior to Rx	≤ 4 hours	≤ 5 hours	≤ 8 hours	6 to 12 hours	≤ 4 hours	≤ 1 hour
Location of treatment	Clinic	Clinic	Clinic	Clinic	Clinic	Home
Duration of observation by HCP	≥ 4 hours	≥ 4 hours	≥ 4 hours	≥ 8 hours	6 hours	none
Treatment administration	HCP	HCP	HCP	HCP	HCP	Patient
Availability of self-administered rescue Rx	None	None	None	None	None	icatibant pdC1INH rhC1INH
Availability of HCP-administered rescue Rx	Second dose of blinded study drug	Second dose of blinded study drug	Opiates, antiemetics	icatibant pdC1INH	rhC1INH icatibant pdC1INH ecallantide	icatibant pdC1INH rhC1INH

BCX7353 Showed Clinically Meaningful and Statistically Significant Benefits

Efficacy Endpoint	BCX7353	Placebo	Difference	P value
<i>VAS Endpoints</i>				
Change from baseline in composite VAS score through 4hr (Least Squares Mean)	-3.9	+3.1	-6.98	0.0024
Proportion of attacks with improved or stable composite VAS score through 4hr	67.7%	46.7%	+21.0%	0.0387
Proportion of attacks with improved or stable composite VAS score through 24hr	62.5%	35.5%	+27.0%	0.0125
Time to stable or improved composite VAS (median)	1 hr	2 hr	-1 hr	0.0452
Time to ≥ 50% reduction in composite VAS through 24 hr (median)	8hr	24hr	-16hr	0.0671
Time to almost complete symptom relief [all 3 individual VAS <10] (median)	23.1 hr	23.6 hr	-0.5 hr	0.6767
<i>Standard of Care Treatment Endpoints</i>				
Proportion of attacks requiring standard of care treatment through 24hr	29.7%	61.3%	-31.6%	0.0029
Time to standard of care acute attack treatment (median)	> 24 hr	14hr	> +10 hr	0.0043
<i>Patient Global Assessment Endpoints</i>				
Proportion of attacks with no or mild symptoms through 4 hr	69.4%	50.0%	+19.4%	0.0552
Proportion of attacks with no or mild symptoms through 24 hr	64.1%	32.3%	+31.8%	0.0038
Proportion of attacks with improved or stable symptoms through 24 hr	64.1%	35.5%	+28.6%	0.0092
Proportion of attacks with improved or stable symptoms through 4 hr	82.3%	60.0%	+22.3%	0.0192
Time to initial symptom relief (median)	5.1 hr	19.4 hr	-14.3 hr	0.0978
Time to complete symptom relief (median)	35.1 hr	41.3 hr	-6.2 hr	0.8900

Rapid and sustained benefit from BCX7353



Values after standard of care treatments are excluded.

¹ The 3-symptom composite VAS was calculated as the average of three individual VAS scores of abdominal pain, cutaneous pain, and cutaneous swelling.

² Comparisons were performed separately at each time point using a mixed effect linear model including treatment, period and sequence as fixed effects, subject within sequence as a random effect, and predose 3-symptom composite VAS score as a covariate.

³ Cox regression model for analysis of clustered data with time to event as the dependent variable and fixed effects for treatment, sequence and period. Subject was included in the model as a cluster variable.

BCX7353 Safe and Well Tolerated in ZENITH-1

Category	BCX7353	Placebo
Number of subjects	33	31
Number of attacks treated*	64	31
Number of attacks with a reported treatment-emergent adverse events (TEAE)	16 (25.0%)	7 (22.6%)
Number of attacks with a serious TEAEs	0	1 (3.2%)
Number of attacks with a drug-related TEAEs as assessed by investigator	7 (10.9%)	4 (12.9%)
Number of attacks with TEAEs leading to permanent discontinuation from study drug	1 (1.6%) ‡	1 (3.2%) §
Number of attacks with TEAEs of Grade 3 or Grade 4	0	0
Number of attacks with TE lab abnormalities of Grade 2, 3, or 4	0	0
Number of attacks with drug-related TEAEs of Grade 3 or 4	0	0
Number of attacks with drug-related serious TEAEs	0	0
Most common adverse events		
<i>Nasopharyngitis</i>	4 (6.3%)	1 (3.2%)
<i>Diarrhea</i>	3 (4.7%)	0
<i>Headache</i>	3 (4.7%)	0


* To account for observation bias, the reported rates take into account the proportion of time considered treatment emergent for BCX7353 and the proportion of time considered treatment emergent for placebo, by using the denominator of number of attacks treated.

‡ Discontinuation on BCX7353 occurred in a subject who developed a small red macule on the forearm 11 hours after taking BCX7353 for an HAE attack occurring in the same anatomic location. The macule lasted for 4 hours and resolved without treatment.

§ Discontinuation on placebo occurred in a subject who experienced abdominal pain on both active and placebo drug. The decision to stop study drug occurred after the placebo dose.

BioCryst Positioned for Success with Multiple Upcoming Data Milestones

- Building a company to develop novel oral therapies for rare diseases, which help patients experience a normal quality of life
- Starting with kallikrein inhibitors for HAE
 - BCX7353 for both prophylaxis and acute therapy
 - First oral therapy—a big deal for patients
 - Strong safety and efficacy profile in clinical trials
- Pipeline behind 7353—Into the clinic next year
 - FOP
 - Additional indication
- Well capitalized
- Next 18 months: ZENITH-1, APeX-2, APeX-S, BCX7353 NDA + MAA, FOP begins phase 1



Baird 2018 Global Healthcare Conference

Jon Stonehouse
Chief Executive Officer

Dr. William Sheridan
Chief Medical Officer

September 6, 2018

